593 related articles for article (PubMed ID: 32014125)
1. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
2. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
4. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
Wagner SM; Melchardt T; Greil R
Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
[No Abstract] [Full Text] [Related]
6. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
[TBL] [Abstract][Full Text] [Related]
7. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
[TBL] [Abstract][Full Text] [Related]
8. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
[TBL] [Abstract][Full Text] [Related]
9. Ropeginterferon alfa-2 b for the therapy of polycythemia vera.
Červinek L
Vnitr Lek; 2020; 66(5):309-313. PubMed ID: 32942868
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á; Pinczés LI; Egyed M
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
[TBL] [Abstract][Full Text] [Related]
13. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
[TBL] [Abstract][Full Text] [Related]
14. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
[TBL] [Abstract][Full Text] [Related]
17. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic approaches in polycythemia vera.
Foucar CE; Stein BL
Clin Adv Hematol Oncol; 2018 Nov; 16(11):750-757. PubMed ID: 30543590
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
[TBL] [Abstract][Full Text] [Related]
20. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Jin J; Zhang L; Qin A; Wu D; Shao Z; Bai J; Chen S; Duan M; Zhou H; Xu N; Zhang S; Zuo X; Du X; Wang L; Li P; Zhang X; Li Y; Zhang J; Wang W; Shen W; Zagrijtschuk O; Urbanski R; Sato T; Xiao Z
Exp Hematol Oncol; 2023 Jun; 12(1):55. PubMed ID: 37344895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
